Amicus Therapeutics, Inc. (NASDAQ:FOLD) Position Reduced by Assetmark Inc.

Assetmark Inc. lowered its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 86.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,842 shares of the biopharmaceutical company's stock after selling 96,746 shares during the period. Assetmark Inc.'s holdings in Amicus Therapeutics were worth $121,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of the business. Summit Investment Advisors Inc. increased its stake in Amicus Therapeutics by 4.4% in the 4th quarter. Summit Investment Advisors Inc. now owns 30,696 shares of the biopharmaceutical company's stock valued at $289,000 after buying an additional 1,280 shares during the period. Diversified Trust Co grew its holdings in Amicus Therapeutics by 2.2% during the first quarter. Diversified Trust Co now owns 83,542 shares of the biopharmaceutical company's stock worth $682,000 after acquiring an additional 1,784 shares during the period. Tempus Wealth Planning LLC boosted its position in shares of Amicus Therapeutics by 7.2% during the 1st quarter. Tempus Wealth Planning LLC now owns 29,513 shares of the biopharmaceutical company's stock worth $241,000 after purchasing an additional 1,990 shares in the last quarter. Covestor Ltd increased its holdings in shares of Amicus Therapeutics by 114.9% in the 4th quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock valued at $41,000 after purchasing an additional 2,312 shares in the last quarter. Finally, Stephens Inc. AR raised its holdings in Amicus Therapeutics by 27.4% during the first quarter. Stephens Inc. AR now owns 13,655 shares of the biopharmaceutical company's stock worth $111,000 after purchasing an additional 2,938 shares during the last quarter.

Amicus Therapeutics Stock Performance

NASDAQ FOLD traded up $0.16 during trading hours on Tuesday, reaching $6.99. The company's stock had a trading volume of 4,595,726 shares, compared to its average volume of 4,337,626. The stock has a market cap of $2.15 billion, a PE ratio of -58.25 and a beta of 0.53. The business has a 50-day simple moving average of $6.06 and a 200 day simple moving average of $7.40. Amicus Therapeutics, Inc. has a 52 week low of $5.51 and a 52 week high of $12.65. The company has a current ratio of 3.21, a quick ratio of 2.29 and a debt-to-equity ratio of 1.92.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. UBS Group lifted their target price on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Morgan Stanley raised Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a research report on Thursday, July 17th. The Goldman Sachs Group decreased their price objective on Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a research note on Friday, May 2nd. Finally, Wall Street Zen upgraded shares of Amicus Therapeutics from a "hold" rating to a "buy" rating in a report on Saturday. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, Amicus Therapeutics has an average rating of "Moderate Buy" and an average target price of $16.22.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.